News | June 15, 2021
Zydus Cadila receives tentative USFDA approval for Brivaracetam
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
Subscribe To Our Newsletter & Stay Updated
